$40,877,324
to UNIVERSITY OF WISCONSIN SYSTEM
CHILDHOOD ASTHMA IN URBAN SETTINGS CLINICAL RESEARCH NETWORK - LEADERSHIP CENTER - PROJECT SUMMARY/ABSTRACT THE OVERALL GOALS OF OUR CHILDHOOD ASTHMA IN URBAN SETTINGS (CAUSE)-LEADERSHIP CENTER PROPOSAL ARE TO PROVIDE ADMINISTRATIVE LEADERSHIP AND SUPPORT TO DEVELOP AND CONDUCT COLLABORATIVE RESEARCH TO ADDRESS HIGH PRIORITY UNMET NEEDS FOR CHILDHOOD ASTHMA IN URBAN COMMUNITIES, INCLUDING: A) DEVELOPING STRATEGIES TO PREVENT ASTHMA, B) IMPROVING TREATMENT AND INHIBITING PROGRESSION, C) REDUCING SEVERE EXACERBATIONS, AND D) DEFINING ENDOTYPES OF RESPIRATORY HEALTH AND DISEASE. FOUR HYPOTHESES ARE PROPOSED TO ACCOMPLISH THESE GOALS. FIRST, SUPPLEMENTATION WITH IMMUNE MODULATING BACTERIA IN INFANCY WILL PREVENT THE EARLY LIFE PERTURBATIONS IN THE GUT MICROBIOME THAT HAVE BEEN ASSOCIATED WITH RISK FOR THE DEVELOPMENT OF ALLERGIC SENSITIZATION AND ASTHMA, AND WILL PROMOTE AIRWAY MUCOSAL IMMUNE DEVELOPMENT. SECOND, GIVEN THE IMPORTANCE OF COCKROACH (CR) ALLERGY AND EXPOSURE TO ASTHMA MORBIDITY IN URBAN CHILDREN, CR IMMUNOTHERAPY WILL IMPROVE ASTHMA CONTROL AND REDUCE DISEASE PROGRESSION. THIRD, WE PROPOSE THAT TRANSCRIPTIONAL ANALYSIS OF AIRWAY CELLS WILL DEFINE T2-LOW MECHANISMS THAT CONTRIBUTE TO BOTH NON-ATOPIC AND ATOPIC ASTHMA AND PROVIDE NEW INSIGHTS INTO TREATMENT. FINALLY, MULTI-OMICS EVALUATION OF AIRWAY CELLS AND SECRETIONS OBTAINED DURING SEVERE EXACERBATIONS LEADING TO ED VISITS AND HOSPITALIZATIONS WILL REVEAL NOVEL MECHANISTIC PATHWAYS TO INFORM IMPROVED TREATMENT AND PREVENTION. WE PROPOSE FIVE PROTOCOLS TO TEST THESE HYPOTHESES: 1. URBAN ENVIRONMENT AND CHILDHOOD ASTHMA STUDY (URECA) 2. EFFECTS OF A MICROBIAL SUPPLEMENT (STMC-103H) ON MICROBIAL COLONIZATION AND IMMUNE DEVELOPMENT 3. COCKROACH (CR) IMMUNOTHERAPY (IT) IN URBAN CHILDREN WITH MODERATE-SEVERE ASTHMA PROTECTED BY OMALIZUMAB 4. PATHOGENESIS AND MECHANISMS OF T2-LOW (NON-ATOPIC) ASTHMA 5. SEVERE ASTHMA EXACERBATIONS IN THE EMERGENCY DEPARTMENT (ED) AND HOSPITAL: IDENTIFYING TARGETS FOR PREVENTION AND TREATMENT IT IS OUR EXPECTATION THAT OUR PROPOSED CAUSE RESEARCH PROGRAM WILL PROVIDE CRITICAL INFORMATION NEEDED TO RECOGNIZE ASTHMA PHENOTYPES AND ENDOTYPES IN URBAN CHILDREN, IMPROVE TREATMENT OF ASTHMA AND ESTABLISH DIRECTION FOR PREVENTION. COLLECTIVELY, THESE STUDIES WILL CONTINUE THE RIGOROUS PROGRAMMATIC APPROACH OF THE NIAID ASTHMA NETWORKS TOWARDS ACHIEVING THE LONG-TERM GOALS OF DISEASE MODIFICATION AND PREVENTION OF DISEASE IN HIGH-RISK CHILDREN OF LOW-INCOME FAMILIES LIVING IN URBAN COMMUNITIES.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Funds a leadership center conducting collaborative clinical research to prevent childhood asthma and improve treatment in urban communities.
Addresses high-burden pediatric respiratory disease in underserved urban populations through novel immunotherapy and mechanistic research approaches.
Drives demand for microbial supplements, immunotherapy reagents, and multi-omics analytical platforms from biotech suppliers.
U.S. investment in advanced asthma therapeutics and precision medicine approaches competes with international biotech innovation in respiratory disease.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002852.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_UM1AI160040_075.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.